Cardiovascular Systems (NASDAQ:CSII) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Tuesday.
Several other research firms have also commented on CSII. BidaskClub upgraded Cardiovascular Systems from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. William Blair restated a “market perform” rating on shares of Cardiovascular Systems in a research note on Thursday, December 21st. Leerink Swann reduced their price objective on Cardiovascular Systems from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Thursday, February 8th. Finally, Zacks Investment Research upgraded Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a research note on Friday, February 9th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. Cardiovascular Systems currently has an average rating of “Hold” and a consensus target price of $27.00.
NASDAQ:CSII opened at $22.69 on Tuesday. The company has a quick ratio of 4.13, a current ratio of 4.65 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $760.37, a PE ratio of 756.33 and a beta of 2.15. Cardiovascular Systems has a one year low of $20.58 and a one year high of $33.11.
Cardiovascular Systems (NASDAQ:CSII) last posted its quarterly earnings data on Wednesday, February 7th. The medical device company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.03. The firm had revenue of $52.63 million during the quarter, compared to analyst estimates of $53.39 million. Cardiovascular Systems had a negative return on equity of 0.50% and a negative net margin of 1.62%. Cardiovascular Systems’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.03 EPS. sell-side analysts expect that Cardiovascular Systems will post -0.07 EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of CSII. New York State Common Retirement Fund boosted its holdings in Cardiovascular Systems by 4.9% in the 3rd quarter. New York State Common Retirement Fund now owns 464,811 shares of the medical device company’s stock worth $13,084,000 after buying an additional 21,507 shares during the period. Wells Fargo & Company MN boosted its holdings in Cardiovascular Systems by 8.4% in the 3rd quarter. Wells Fargo & Company MN now owns 47,253 shares of the medical device company’s stock worth $1,330,000 after buying an additional 3,648 shares during the period. Sterling Capital Management LLC boosted its holdings in Cardiovascular Systems by 15.8% in the 3rd quarter. Sterling Capital Management LLC now owns 59,527 shares of the medical device company’s stock worth $1,676,000 after buying an additional 8,122 shares during the period. Thomson Horstmann & Bryant Inc. bought a new position in Cardiovascular Systems in the 4th quarter worth $3,463,000. Finally, Bank of Montreal Can boosted its holdings in Cardiovascular Systems by 12.5% in the 4th quarter. Bank of Montreal Can now owns 53,889 shares of the medical device company’s stock worth $1,277,000 after buying an additional 5,998 shares during the period. 82.56% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/17/cardiovascular-systems-csii-cut-to-strong-sell-at-valuengine.html.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.